The research firm’s primary aim is to provide comprehensive treatment solutions for various skin diseases, in particular vitiligo, a depigmenting disease with elusive mechanisms. - Issue Date: Jan 21, 2024
'There are many challenges that women face in the investment industry, with some investors hesitant to invest in a company led by a woman due to perceived commitment issue'
Pune-based startup Ahammune Biosciences raises funds to develop vitiligo drug
Pune-based startup Ahammune Biosciences raises funds to develop vitiligo drug
26 April 2021 | News The fresh funds raised will be utilized for “first-in-human” studies with Ahammune’s new drug candidate AB1001 for vitiligo
Image credit- shutterstock.com
Pune-based biotech startup company, Ahammune Biosciences has raised an undisclosed amount in a Pre-Series A round led by Ideaspring Capital and Indian Angel Network. Kotak Private Equity, Legacy Assets LLP (Baldota family fund), and Dr. Ajith Kamath (ex-Pfizer) have also participated in the round along with existing investors, including Dr. Anand Deshpande and Suman Kant Munjal. The Company also has Dr. Ganesh Natarajan as an existing investor and has been in receipt of funding grant from Government of India’s body, BIRAC.